A Phase 3, Double-blind, Randomized, Multicenter Study Evaluating the Efficacy and Safety of Filgotinib versus Placebo and Adalimumab in TNF Naïve Subjects with Moderately to Severely Active Crohn’s Disease 27 de Setembro, 2019 By admin